SEC For	rm 4																			
FORM 4 UNITED STA				TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549													OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See						NT OF CHANGES IN BENEFICIAL OWNERSHIP ed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person [*] Durgam Suresh K. (Last) (First) (Middle) C/O INTRA-CELLULAR THERAPIES, INC.				<u>In</u> 3. [2. Issuer Name and Ticker or Trading Symbol <u>Intra-Cellular Therapies, Inc.</u> [ITCI] 3. Date of Earliest Transaction (Month/Day/Year) 03/01/2024								(Che	Relationship of Reporting Person(s) to Issuer neck all applicable) Director 10% Owner X Officer (give title Other (specify below) EVP, Chief Medical Officer				wner specify		
430 EAST 29TH STREET (Street) NEW YORK NY 10016				4. li	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Indi Line) X									,						
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D)				action	ar) i	2A. Deemed Execution Date, if any (Month/Day/Year		3. 4. Transaction Dis Code (Instr. 5)		4. Securit Disposed	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5. Amoun Securitie Beneficia Owned F Reported	nt of s ally following	Form (D) o	n: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				41.00	ive Securities Acqu			Code V		Amount	(A) (D)		Price	Transaction(s) (Instr. 3 and 4)				,		
				(e.g., p			s, warr	ants	s, options	, co	onvertil	ble sec	uriti	es)						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable a Expiration Date (Month/Day/Year)			7. Title and Ar of Securities Underlying Derivative Sec (Instr. 3 and 4		urity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	or Nui of	nount mber ares						
Restricted Stock Units	(1)	03/01/2024			А		26,227		(2)		(2)	Common Stock	¹ 26	,227	\$ 0	26,22	.7	D		

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

2. On March 1, 2024, the reporting person was granted 26,227 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

<u>/s/ Lawrence J. Hineline,</u> <u>Attorney-in-fact</u>	03/05/2024
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.